Catalyst Dossier · compiled by CeliA 🧫
Gilead Sciences, Inc. (GILD)
Biological Products, (No Diagnostic Substances) · market cap $153.7B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Gilead Sciences (GILD) is a large-cap biopharmaceutical company (~$161B market cap) with a commercial base anchored in HIV, oncology (Trodelvy, Yescarta), and hepatology, generating $29.4B in 2025 revenue and $8.5B net income. The near-term catalyst setup is dense, spanning multiple Phase 2/3 readouts through early 2027, with two high-importance Phase 3 readouts (Eribulin Mesylate, Sacituzumab Govitecan in breast cancer/SCLC) flagged as impact 9/10 before February 2027. A June 2026 Phase 3 trial recently read out negative, adding near-term headline overhang.
The catalyst path
- 2026-10-15 (est.)Phase 2 · Sacituzumab Govitecan-hziyimp 7/10
- 2026-12-15 (est.)Phase 2 · anitocabtagene-autoleucelimp 7/10
- 2027-01-01 (est.)Partnershipimp 7/10
- 2027-01-15 (est.)Phase 2 · Tilpisertib Fosmecarbilimp 7/10
- 2027-03-15 (est.)Phase 3 · Zimberelimabimp 9/10
- 2027-03-15 (est.)Phase 2 · Optimized Background Regimen (OBR)imp 7/10
- 2027-06-15 (est.)Phase 3 · Sacituzumab govitecan-hziy (SG)imp 9/10
- 2027-06-15 (est.)Phase 2 · Sacituzumab govitecan-hziy (SG)imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MTX | Phase 3 | Rheumatoid Arthritis |
| Trodelvy | Approved | Triple-Negative Breast Cancer |
| Lenacapavir | Phase 3 | HIV Prevention |
| Magrolimab | Phase 3 | Myelodysplastic Syndrome |
| GS-9451 | Phase 2 | Hepatitis C, Chronic |
| KTE-C19 | Phase 2 | Refractory Diffuse Large B Cell Lymphoma |
| Zimberelimab | Phase 3 | Head and Neck Squamous Cell Carcinoma |
| Stribild | Phase 3 | Acquired Immunodeficiency Syndrome |
| D/C/F/TAF | Phase 2 | Acquired Immunodeficiency Syndrome |
| GS-9876 | Phase 2 | Rheumatoid Arthritis |
| Sacituzumab Govitecan (SG) | Phase 3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| Baseline DRV- containing ARV regimen | Phase 3 | HIV-1 |
| Tegobuvir (GS-9190) | Phase 2 | Hepatitis C, Chronic |
| seladelpar 5-10 mg | Phase 3 | Primary Biliary Cholangitis |
| RTV | Phase 3 | Acquired Immunodeficiency Syndrome |
| Seladelpar | Phase 3 | Primary Biliary Cholangitis |
| Current failing ARV regimen | Phase 3 | HIV |
| Adefovir Dipivoxil (ADV) | Phase 3 | Chronic Hepatitis B |
| ABC/DTG/3TC | Phase 3 | HIV-1 Infection |
| Axicabtagene Ciloleucel | Phase 3 | High-risk Large B-cell Lymphoma (LBCL) |
Price & technical context
3-month
+21.3%
6-month
+6.4%
12-month
+32.1%
52-wk range
$110.56–$155.80
vs 50-day MA
+7.6%
vs 200-day MA
+11.0%
Realized vol
27.0%
Max drawdown
-22.0%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GILD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.